Rezultaty 1 - 6 Rezultaty od 6 Dla wyszukiwania 'Flynt, E', Czas wyszukiwania: 0,02s
Redukuj rezultaty
-
1
-
2
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma od Amatangelo, M, Flynt, E, Stong, N, Ray, P, Van Oekelen, O, Wang, M, Ortiz, M, Maciag, P, Peluso, T, Parekh, S, van de Donk, NWCJ, Lonial, S, Thakurta, A
Wydane 2024Journal article -
3
Loss of COP9 signalosome gene-containing 2q region is associated with lenalidomide and pomalidomide resistance in myeloma patients od Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Salazar, MA, Fitzsimons, E, Estevez, MO, Towfic, F, Flynt, E, Pierceall, WE, Yong, K, Vyas, P, Thakurta, A
Wydane 2021Conference item -
4
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma od Gooding, S, Ansari-Pour, N, Towfic, F, Ortiz Estévez, M, Chamberlain, PP, Tsai, K-T, Flynt, E, Hirst, M, Rozelle, D, Dhiman, P, Neri, P, Ramasamy, K, Bahlis, N, Vyas, P, Thakurta, A
Wydane 2020Journal article -
5
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma od Van Oekelen, O, Amatangelo, M, Guo, M, Upadhyaya, B, Cribbs, AP, Kelly, G, Patel, M, Kim-Schulze, S, Flynt, E, Lagana, A, Gooding, S, Merad, M, Jagganath, S, Pierceall, WE, Oppermann, U, Thakurta, A, Parekh, S
Wydane 2024Journal article -
6
Loss Of COP9-signalosome genes Aa 2q37 is associated with IMiD agent resistance in multiple myeloma od Gooding, S, Ansari-Pour, N, Kazeroun, MH, Karagoz, K, Polonskaia, A, Angulo Salazar, M, Fitzsimons, E, Sirinukunwattana, K, Chavda, SJ, Ortiz Estevez, M, Towfic, F, Flynt, E, Pierceall, W, Royston, D, Yong, KL, Ramasamy, K, Vyas, P, Thakurta, A
Wydane 2022Journal article